Search | Clinical Trials Finder

Conditions: Major Depressive Disorder (MDD)
Interventions: Escitalopram, Aripiprazole, Blinded capsule; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 24
States / cities: Cerritos, California • Costa Mesa, California • Irvine, California + 21 more

Conditions: Major Depressive Disorder
Interventions: Low Dose Fish Oil, High Dose Fish Oil; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 12 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder
Interventions: Placebo, RO4995819; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 43
States / cities: Phoenix, Arizona • Oakland, California • Redlands, California + 37 more

Conditions: Major Depressive Disorder
Interventions: Levomilnacipran ER, Paroxetine, Sertraline, Citalopram or Fluoxetine., Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 20
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 17 more

Conditions: Depression
Interventions: Problem Solving Therapy, Dietary Education; Behavioral
Lead sponsor: University of Maryland, College Park; Other
Eligibility: 50 Years and older
Enrollment: 306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Intranasal Placebo, Midazolam Placebo Solution, Midazolam, Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 18
States / cities: Hartford, Connecticut • New Haven, Connecticut • Atlanta, Georgia + 15 more

Conditions: Major Depressive Disorder, MDD, Generalized Anxiety Disorder, GAD, Depression, Anxiety
Interventions: Ampa One TMS System; Device
Lead sponsor: Biomedical Discoveries and Neuroscientific Foundations LLC; Industry
Eligibility: 12 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: Encinitas, California • Plano, Texas

Conditions: Major Depressive Disorder, Generalized Anxiety Disorder
Interventions: Quetiapine XR, Placebo; Drug
Lead sponsor: Keming Gao; Other
Eligibility: 18 Years to 70 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Major Depressive Disorder
Interventions: Cytomel (liothyronine); Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder, Opioid Use Disorder, Suicidality
Interventions: Repetitive Transcranial Magnetic Stimulation; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Major Depressive Disorder
Interventions: NBI-1065845, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Huntsville, Alabama • Bryant, Arkansas • Glendale, California + 14 more

Conditions: Major Depressive Disorder
Interventions: Combination Product: BCI-024 + BCI-049; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 9
States / cities: Garden Grove, California • San Diego, California • Altanta, Georgia + 6 more

Conditions: Major Depressive Disorder
Interventions: Open-label TMS; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depressive Disorder, Major
Interventions: JNJ-67953964, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 28
States / cities: Tucson, Arizona • Little Rock, Arkansas • Glendale, California + 23 more

Conditions: Depression
Interventions: Guided Mindfulness Practice using a study created web app that links to the commercially available Waking Up app; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Major Depressive Disorder, Anxiety
Interventions: transcranial direct current stimulation using a Soterix mini-CT device; Device
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 28 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Treatment Resistant Depression, Inflammation, Overweight
Interventions: Omega 3, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: repetitive transcranial magnetic stimulation, robotic arm; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bipolar I Disorder
Interventions: Not listed
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 423 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 9
States / cities: Costa Mesa, California • Cromwell, Connecticut • Doral, Florida + 5 more

Conditions: Major Depressive Disorder, Major Depressive Episode
Interventions: Universal Screening Arm; Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 12,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Depression, Cognition
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years and older
Enrollment: 311 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Middleton, Wisconsin

Conditions: Major Depressive Disorder, Depression
Interventions: TMS; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Major Depressive Disorder (MDD)
Interventions: Radafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 29
States / cities: Little Rock, Arkansas • Newport Beach, California • Farmington, Connecticut + 25 more

Conditions: Major Depressive Disorder
Interventions: Escitalopram, Bupropion XL; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

Omega-3 Fatty Acids as Adjunct Treatment for Major Depressive Disorder

ARTDeCo Study: A Study of RO4995819 in Patients With Major Depressive Disorder And Inadequate Response to Ongoing Antidepressant Treatment

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive Disorder

Primary Prevention of Major Depression in Later Life

Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide

Operation of Brain Stimulation Equipment Under Remote Viewing Effectiveness Registry

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder

Biochemical Brain Changes Correlated With The Antidepressant Effect Of Thyroid Hormones

Cortical rTMS as a Treatment for Depression

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)

In-patient SCC TMS

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

Mindfulness Training During Accelerated TMS for Depression

Biomarkers of Response to Treatment With Frontal Cortex Stimulation for Anxious Depression

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Treatment of Depression With Connectivity Guided Robotically Delivered rTMS

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World Setting

Universal vs. Targeted School Screening for Adolescent Major Depressive Disorder

Study of Duloxetine in Elderly Patients With Major Depressive Disorder

Brain-Based Biomarkers in Response to TMS in MDD

An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder

Connectivity Affecting the Antidepressant REsponse Study